Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma
Mené sur 549 patients atteints d'un lymphome hodgkinien de stade III ou IV, cet essai européen de phase III compare l'efficacité, du point de vue de la survie sans événement et plusieurs autres critères, et la toxicité de deux protocoles de chimiothérapie, ABVD8 et BEACOPP4+4
Advanced-stage Hodgkin lymphoma (HL) used to be a fatal malignancy. This has changed with the advent of multiagent chemotherapy. However, with an increasing number of patients being cured, acute and long-term adverse effects of chemotherapy and radiotherapy have become more relevant and need to be taken into account when planning new treatments....
Journal of Clinical Oncology , éditorial en libre accès, 2016